• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Revelyst Announces Chief Supply Chain Officer

    4/23/24 7:00:00 AM ET
    $BDX
    $EMBC
    $VSTO
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer.

    Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply chain, sourcing and logistics leader is key to helping Revelyst and its brands begin this new chapter.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423438660/en/

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Beck most recently served as Vice President of Global Supply Chain for embecta (NASDAQ:EMBC), a medical technology company where he oversaw global supply chain and distribution operations, including the overhaul of their global network design, planning, logistics, and trade technology and change management leadership. Beck was part of embecta's leadership team executing the separation from Becton Dickinson and Co. (NYSE:BDX). During the transition, he helped establish the company's supply chain infrastructure while ensuring continuity of supply and mitigating customer disruptions. His ability to design and deploy global supply chain operations for a standalone business — including hiring talent, building effective teams and developing processes, analytics and technology — made him an ideal candidate to be Revelyst's first Chief Supply Chain Officer.

    "Bringing a change agent like Joe to Revelyst's leadership team is critical for our goal of becoming the industry's No. 1 house of brands," said Eric Nyman, CEO of Revelyst. "He has a unique talent for transforming a company's supply chain by consolidating facilities and building new capabilities, which have a direct impact on the bottom line. Joe will help revolutionize Revelyst at the enterprise, platform and brand level, and we welcome his innovative thinking as we continue to build our culture of empowerment and excellence."

    Before embecta, Beck worked for Medtronic and UPS, two global Fortune 500 companies where he streamlined and optimized supply chain operations, which he will replicate and enhance in this new role. Beck is the latest executive to join Revelyst's growing management team, including Nyman, CFO Andy Keegan, General Counsel Jung Choi and CHRO Joyce Butler. The addition of Beck will provide Revelyst with the supply chain and sourcing savvy needed in an increasingly competitive and complex global economy.

    "This is the opportunity of a lifetime because it combines my outdoor passions with my love of helping companies become more efficient and effective moving products and information across the global supply chain," said Beck. "I look forward to building a world-class team whose sole focus is optimizing the way Revelyst does business, building scale across our portfolio and developing innovative strategies that give our company and our brands a significant competitive advantage to accelerate growth."

    About Revelyst

    Revelyst, a segment of Vista Outdoor Inc. (NYSE:VSTO), is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240423438660/en/

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX
    $EMBC
    $VSTO

    CompanyDatePrice TargetRatingAnalyst
    Becton Dickinson and Company
    $BDX
    2/3/2026$233.00Buy
    Citigroup
    Becton Dickinson and Company
    $BDX
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    Becton Dickinson and Company
    $BDX
    5/22/2025$185.00Buy → Neutral
    Citigroup
    Becton Dickinson and Company
    $BDX
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    Becton Dickinson and Company
    $BDX
    5/2/2025$192.00Buy → Neutral
    Goldman
    Becton Dickinson and Company
    $BDX
    5/2/2025Outperform → Mkt Perform
    Raymond James
    Becton Dickinson and Company
    $BDX
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Becton Dickinson and Company
    $BDX
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BDX
    $EMBC
    $VSTO
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/5/26 4:21:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/5/26 4:17:15 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Embecta Corp.

    10-Q - Embecta Corp. (0001872789) (Filer)

    2/5/26 11:26:03 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    BD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care

    Study Opens Door to Sustainable Path for Polystyrene Petri Dishes, PET Tubes, Medical Tubing, and Polypropylene Syringes Across Healthcare Supply Chains FRANKLIN LAKES, N.J. and BIRDHILL, Colo. and TIPPERARY, Ireland, Jan. 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Envetec Sustainable Technologies ("Envetec"), announced today the successful completion of a joint feasibility study to test the ability to recycle polystyrene Petri dishes into new, high-quality manufacturing feedstock. The results of the

    1/29/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Urbini Massimiliano claimed ownership of 4,133 shares (SEC Form 3)

    3 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/6/26 2:31:33 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/5/26 12:24:15 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Byington Carrie L

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/5/26 12:21:44 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BDX
    $EMBC
    $VSTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Citigroup resumed coverage on Becton Dickinson with a new price target

    Citigroup resumed coverage of Becton Dickinson with a rating of Buy and set a new price target of $233.00

    2/3/26 6:55:14 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Citigroup with a new price target

    Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

    5/22/25 8:18:13 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

    FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

    7/7/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    12/2/24 4:30:15 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    11/27/24 12:42:04 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Financials

    Live finance-specific insights

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

    FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share. The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations pr

    1/27/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care